Testing a Pill Called JZP3507 for Grade 2 or 3 Meningioma That Came Back
Official title: A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing a pill for people whose grade 2 or 3 meningioma came back after earlier treatment.
Read our full plain-language summary
What the trial team says
This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.
Key facts
- Registry number
- NCT07533942
- Stage of testing
- Phase 2
- Conditions studied
- Meningioma
Where it is running
This trial lists 5 sites.
-
California
- Sutter Health (San Francisco)
-
Louisiana
- Louisiana State University (New Orleans)
-
Massachusetts
- Mass General (Boston)
-
New York
- NYU- Langone Health (New York)
-
Utah
- University of Utah - Huntsman Cancer Institute (Salt Lake City)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.